
B/m/vinci8/data1/riedel/corpora/nyt/nyt/data/2006/07/18/1776863.xml’

TheDTO

pharmaceuticalJJO

industryNNO

isVBZO

	beginningVBGO

toTOO

reapVBO


aDTO

windfallNNO

fromINO


aDTO

surprisinglyRBO

	lucrativeJJO

nicheNNO

marketNNO
	
::O

drugsNNSO

forINO

poorJJO

peopleNNSO
	
..O¸

AndCCO

analystsNNSO

expectVBPO

theDTO

benefitsNNSO

toTOO

showVBO

upRPO

inINO

manyJJO

ofINO

theDTO

	quarterlyJJO

	financialJJO

resultsNNSO

thatINO

drugNNO

makersNNSO

willMDO

beginVBO

postingVBGO

thisDTO

weekNNO
	
..Oê

TheDTO

windfallNNO
	
,,O

whichWDTO

byINO

someDTO

	estimatesNNSO

couldMDO

beVBO
	
$$O


2CDO

billionCDO

orCCO

moreRBRO

thisDTO

yearNNO
	
,,O

isVBZO


aDTO

resultNNO

ofINO

theDTO

transferNNO

ofINO

millionsNNSO

ofINO


low-incomeJJO

peopleNNSO

intoINO

theDTO

newJJO

MedicareNNPO

PartNNPO

DNNPO

drugNNO

programNNO

thatWDTO

wentVBDO

intoINO

effectNNO

inINO

JanuaryNNPO
	
..O¡

UnderINO

thatDTO

programNNO
	
,,O

asINO

itPRPO

turnsVBZO

outRPO
	
,,O

theDTO

pricesNNSO

paidVBNO

byINO

insurersNNSO
	
,,O

andCCO


eventuallyRBO

theDTO

taxpayerNNO
	
,,O

forINO

theDTO

medicationsNNSO

givenVBNO

toTOO

thoseDTO

transferredVBNO

areVBPO

likelyJJO

toTOO

beVBO

higherJJRO

thanINO

whatWPO

wasVBDO

paidVBNO

underINO

theDTO

federal-stateJJO

MedicaidNNPO

programsNNSO

forINO

theDTO

poorJJO
	
..OÇ

AboutINO

6.5CDO

millionCDO


low-incomeJJO

elderlyJJO

peopleNNSO

orCCO

youngerJJRO

disabledJJO

poorJJO

peopleNNSO

wereVBDO

automaticallyRBO

transferredVBNO

intoINO

theDTO

PartNNO

DNNPO

programNNO

forINO

drugNNO

coverageNNO
	
..Oî

BecauseINO

theirPRP$O

otherJJO

healthNNO

needsNNSO

areVBPO

stillRBO

coveredVBNO

byINO

MedicaidNNPO
	
,,O

theyPRPO

areVBPO

calledVBNO

dualJJO

	eligiblesNNSO
	
..OÕ

TheDTO

adventNNO

ofINO

PartNNO

DNNPO

hasVBZO

notRBO

affectedVBNO

theDTO

drugNNO

coverageNNO

forINO

theDTO

45CDO

millionCDO

otherJJO


low-incomeJJO

peopleNNSO

whoseWP$O

drugsNNSO

areVBPO

stillRBO

paidVBNO

forINO

underINO

stateNNO

MedicaidNNPO

programsNNSO
	
..O¿

ThoseDTO

programsNNSO

closelyRBO

monitorVBPO

drugNNO

pricesNNSO
	
,,O

andCCO

drugNNO

makersNNSO

oftenRBO

	typicallyRBO

endVBO

upRPO

payingVBGO

rebatesNNSO

toTOO

theDTO

statesNNSO
	
..O€

ItPRPO

isVBZO

tooRBO

earlyJJO

toTOO

	calculateVBO

theDTO

fullJJO

effectNNO

ofINO

theDTO

shiftNNO

ofINO

theDTO

formerJJO

MedicaidNNPO

patientsNNSO

nowRBO

coveredVBNO

byINO

PartNNPO

D.NNPO

ButCCO

analystsNNSO

expectVBPO

itPRPO

toTOO

generateVBO

hundredsNNSO

ofINO

millionsNNSO

ofINO


additionalJJO

dollarsNNSO

thisDTO

yearNNO

forINO

theDTO

drugNNO

	companiesNNSO
	
,,O

whichWDTO

haveVBPO

longRBO

chafedVBNO

underINO

theDTO

pricingNNO


restraintsNNSO

ofINO

theDTO

stateNNO

programsNNSO
	
..O±

DrugsNNSO

tendVBPO

toTOO

beVBO

cheaperJJRO

underINO

theDTO

MedicaidNNPO

programsNNSO

becauseINO

theDTO

statesNNSO

areVBPO

theDTO

buyersNNSO

andCCO

byINO

lawNNO

theyPRPO

receiveVBPO

theDTO

lowestJJSO

	availableJJO

pricesNNSO

forINO

drugsNNSO
	
..Oª

ButCCO

inINO

creatingVBGO

theDTO

federalJJO

PartNNO

DNNPO

programNNO
	
,,O

CongressNNPORGANIZATION


--:O

inINO

whatWPO

criticsNNSO

sawVBDO

asINO


aDTO

sopNNO

toTOO

theDTO

drugNNO

industryNNO


--:O

barredVBNO

theDTO


governmentNNO

fromINO

havingVBGO


aDTO

negotiatingVBGO

roleNNO
	
..OEÇÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000000f0ca5	 	*ORGANIZATIONÜ

InsteadRBO
	
,,O

pricesNNSO

areVBPO

workedVBNO

outRPO

betweenINO

drugNNO

makersNNSO

andCCO

theDTO

dozensNNSO

ofINO

largeJJO

andCCO

smallJJO

PartNNO

DNNPO

drugNNO

plansNNSO

runVBNO

byINO


commercialJJO

insurersNNSO
	
..Oê

SinceINO

PartNNO

DNNPO

wentVBDO

intoINO

effectNNO
	
,,O

theDTO

pharmaceuticalJJO

industryNNO

hasVBZO

raisedVBNO

theDTO

	wholesaleJJO

pricesNNSO

ofINO

itsPRP$O


brand-nameNNO

drugsNNSO

anDTO

averageNNO

ofINO

3.6CDO

percentNNO
	
..O≤

AlthoughINO

theDTO

actualJJO

amountNNO

spentVBNO

dependsVBZO

onINO

whatWPO

eachDTO

insurerNNO


negotiatesVBZO
	
,,O

inINO

manyJJO

casesNNSO

theDTO

drugsNNSO

forINO

thoseDTO

6.5CDO

millionCDO

peopleNNSO

whoWPO

usedVBDO

toTOO

receiveVBO

theirPRP$O

	medicinesNNSO

throughINO

MedicaidNNPO

willMDO

costVBO

moreJJRO

nowRBO
	
..O…

	InitiallyRBO
	
,,O

theDTO

addedVBNO

costsNNSO

willMDO

beVBO

paidVBNO

byINO

theDTO

insurersNNSO

administeringVBGO

theDTO

newJJO

MedicareNNPORGANIZATION

drugNNO

programNNO
	
..OÉÄÄÄ¯ˇˇˇˇ *ORGANIZATION™

ButCCO

whenWRBO

itPRPO

comesVBZO

timeNNO

forINO

theDTO

insurersNNSO

toTOO

settleVBO

accountsNNSO

withINO

theDTO


governmentNNO
	
,,O

theDTO

costsNNSO

ofINO

theDTO

6.5CDO

millionCDO

drugsNNSO

forINO

theDTO

transfereesNNSO

willMDO

endVBO

upRPO

beingVBGO

passedVBNO

alongINO

toTOO

federalJJO

	taxpayersNNSO
	
,,O

	accordingVBGO

toTOO

analystsNNSO

andCCO

healthNNO

careNNO


economistsNNSO
	
..O¬

TheDTO

windfallNNO

forINO

theDTO

drugNNO

makersNNSO

wasVBDO

madeVBNO

possibleJJO

byINO


aDTO

	provisionNNO

ofINO

theDTO

2003CDO

MedicareNNPO

lawNNO

thatWDTO

exemptsVBZO

PartNNO

DNNPO

drugsNNSO

fromINO

''PRP$O

bestJJSO

priceNNO

''''O

rebatesNNSO

thatINO

theDTO

drugNNO

makersNNSO

haveVBPO

beenVBNO

requiredVBNO

toTOO

giveVBO

toTOO

theDTO

stateNNO

MedicaidNNPO

programsNNSO

sinceINO

1991CDO
	
..O∞

ThoseDTO

rebatesNNSO

areVBPO

meantVBNO

toTOO

makeVBO

sureJJO

thatINO

stateNNO

MedicaidNNPO

agenciesNNSO

payVBPO

noDTO

moreJJRO

thanINO

theDTO

bestJJSO

pricesNNSO

drugNNO

	companiesNNSO

offerVBPO

toTOO

anyDTO

bigJJO


commercialJJO

insurerNNO
	
..Oå

UnderINO

MedicaidNNPO
	
,,O

theDTO

federalJJO


governmentNNO

andCCO

stateNNO

agenciesNNSO

paidVBDO

moreJJRO

thanINO
	
$$O

14CDO

billionCDO

annuallyRBO

forINO

theDTO

drugsNNSO

ofINO

theDTO

6.5CDO

millionCDO

transfereesNNSO
	
..OÕ

WithoutINO

theDTO


best-priceJJO

rebatesNNSO
	
,,O

theDTO

costNNO

wouldMDO

haveVBO

beenVBNO

25CDO

percentNNO

higherJJRO
	
,,O

orCCO

aboutINO
	
$$O

17.5CDO

billionCDO
	
,,O

saidVBDO

StephenNNPPERSON

W.NNPPERSON

SchondelmeyerNNPPERSON
	
,,O


aDTO

	professorNNO

ofINO

pharmaceuticalJJO

	economicsNNSO

atINO

theDTO


UniversityNNPORGANIZATION

ofINORGANIZATION

	MinnesotaNNPORGANIZATION
	
..OEÑÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000022e871  "*ORGANIZATIONÖÄÄÄ¯ˇˇˇˇ *PERSONÏ

NobodyNNO

yetRBO

knowsVBZO

whatWPO

theDTO

totalJJO

drugNNO

billNNO

willMDO

beVBO

forINO

theseDTO

peopleNNSO

underINO

PartNNORGANIZATION

DNNPORGANIZATION
	
,,O

beyondINO

theDTO


assumptionNNO

byINO

manyJJO

expertsNNSO

thatINO

itPRPO

willMDO

beVBO

higherJJRO
	
..OÜÄÄÄ¯ˇˇˇˇ *ORGANIZATIONﬂ

MedicareNNPORGANIZATION

willMDO

notRBO

haveVBO

solidJJO

numbersNNSO

untilINO

itPRPO

canMDO

analyzeVBO

theDTO

hundredsNNSO

ofINO

monthlyJJO

reportsNNSO

thatINO

theDTO

plansNNSO

inINO

theDTO

PartNNO

DNNPO

systemNNO

areVBPO

requiredVBNO

toTOO

fileVBO
	
..OáÄÄÄ¯ˇˇˇˇ   *ORGANIZATION 

YetRBO
	
,,O

oneCDO

	indicatorNNO

ofINO

theDTO

higherJJRO

revenueNNO

fromINO

dual-eligiblesNNSO

hasVBZO

alreadyRBO

beenVBNO

seenVBNO

inINO

reportsNNSO

byINO

drugNNO

	companiesNNSO

thisDTO

yearNNO

showingVBGO

double-digitJJO

UnitedNNPLOCATION

StatesNNPSLOCATION

salesNNSO

	increasesNNSO

ofINO

certainJJO

drugsNNSO

thatWDTO

areVBPO

heavilyRBO

usedVBNO

byINO

MedicaidNNPO

patientsNNSO
	
..OAàÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000045917bf *LOCATIONº


ForINO

exampleNNO
	
,,O

salesNNSO

ofINO

LamictalNNPORGANIZATION
	
,,O

anDTO

antipsychosisNNO

drugNNO

fromINO
$
GlaxoSmithKlineNNPORGANIZATION
	
,,O

wereVBDO

upRBO

33CDO

percentNNO
	
,,O

toTOO
	
$$O

305CDO

millionCDO

inINO

theDTO

firstJJO

quarterNNO
	
;:O

salesNNSO

ofINO

SeroquelNNPO
	
,,O

anDTO

antipsychoticJJO

fromINO
 
AstraZenecaNNPORGANIZATION
	
,,O

wereVBDO

upINO

29CDO

percentNNO
	
,,O

toTOO
	
$$O

590CDO

millionCDO
	
;:O

andCCO

salesNNSO

ofINO

PlavixNNPLOCATION
	
,,O


aDTO

bloodNNO

thinnerNNO

fromINO

Bristol-MyersNNPLOCATION

SquibbNNPLOCATION
	
,,O

wereVBDO

upINO

26CDO

percentNNO
	
,,O

toTOO
	
$$O

850CDO

millionCDO
	
..OAâÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000027bc207 8*LOCATIONäÄÄÄ¯ˇˇˇˇ1 1*LOCATIONEãÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000247958" "*ORGANIZATIONEåÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000152a67 *ORGANIZATIONçÄÄÄ¯ˇˇˇˇ *ORGANIZATION¡

TimothyNNPPERSON

AndersonNNPPERSON
	
,,O


aDTO

pharmaceuticalJJO

analystNNO

withINO

theDTO


PrudentialNNPORGANIZATION

EquityNNPORGANIZATION

GroupNNPORGANIZATION
	
,,O

	estimatesVBZO

thatINO

ifINO

PartNNO

DNNPO

wereVBDO

notRBO

inINO

placeNNO

theDTO

rebatesNNSO

forINO

theDTO

makersNNSO

forINO

allDTO

ofINO

2006CDO

wouldMDO

haveVBO

beenVBNO

moreJJRO

thanINO
	
$$O


2CDO

billionCDO

forINO

13CDO

drugsNNSO

widelyRBO

usedVBNO

byINO

theDTO

peopleNNSO

transferredVBNO

fromINO

MedicaidNNPO

toTOO

PartNNPPERSON

D.NNPPERSON

Dr.NNPPERSON

AndersonNNPPERSON

	estimatesVBZO

thatINO

becauseINO

theDTO

	companiesNNSO

willMDO

notRBO

haveVBO

toTOO

payVBO

thoseDTO

rebatesNNSO

underINO

PartNNORGANIZATION

DNNPORGANIZATION
	
,,O

revenueNNO

toTOO

GlaxoNNPORGANIZATION

fromINO

LamictalNNPORGANIZATION

willMDO

increaseVBO

byINO
	
$$O

298CDO

millionCDO

thisDTO

yearNNO
	
,,O
 
AstraZenecaNNPORGANIZATION

'sPOSO

SeroquelNNO

salesNNSO

willMDO

riseVBO

byINO
	
$$O

521CDO

millionCDO
	
,,O

andCCO

PlavixNNPO

revenueNNO

willMDO

increaseVBO
	
$$O

169CDO

millionCDO
	
..OEéÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000247958T T*ORGANIZATIONèÄÄÄ¯ˇˇˇˇJ J*ORGANIZATIONêÄÄÄ¯ˇˇˇˇH H*ORGANIZATIONëÄÄÄ¯ˇˇˇˇC D*ORGANIZATIONíÄÄÄ¯ˇˇˇˇ2 5*PERSONìÄÄÄ¯ˇˇˇˇ 
*ORGANIZATIONîÄÄÄ¯ˇˇˇˇ  *PERSON¶

	EstimatesNNSO

onINO

theDTO

rebateNNO

	increasesVBZO

becauseINO

ofINO

PartNNO

DNNPO

areVBPO

fewJJO
	
,,O

butCCO

allDTO

areVBPO

inINO

generalJJO

	agreementNNO

onINO

theDTO

sizeNNO

ofINO

theDTO

rebateNNO

toTOO

drugNNO

makersNNSO
	
..Oï

MedicaidNNPO

programsNNSO

haveVBPO

beenVBNO


especiallyRBO

	importantJJO

forINO

drugsNNSO

likeINO

SeroquelNNPORGANIZATION

andCCO

LamictalNNPORGANIZATION
	
,,O

whichWDTO

areVBPO


prescribedVBNO

forINO

bipolarJJO

disorderNNO

andCCO

otherJJO

mentalJJO

healthNNO

problemsNNSO

AboutINO

twoCDO

millionCDO

ofINO

theDTO

peopleNNSO

transferredVBNO

toTOO

PartNNO

DNNPO

areVBPO

disabledJJO

andCCO

youngerJJRO

thanINO

65CDO
	
,,O

andCCO

''''O

moreJJRO

thanINO

halfNNO

ofINO

themPRPO

haveVBPO

mentalJJO

healthNNO

problemsNNSO
	
,,O

''''O

saidVBDO

JimNNPPERSON

VerdierNNPPERSON
	
,,O


aDTO

seniorJJO

fellowNNO

atINO
 
MathematicaNNPORGANIZATION

PolicyNNPORGANIZATION

ResearchNNPORGANIZATION

inINO


WashingtonNNPLOCATION

andCCO


aDTO

formerJJO

MedicaidNNPO

directorNNO

inINO

IndianaNNPLOCATION
	
..O

''''OAïÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000001e838I I*LOCATIONAñÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000000407bbB B*LOCATIONóÄÄÄ¯ˇˇˇˇ> @*ORGANIZATIONòÄÄÄ¯ˇˇˇˇ7 8*PERSONôÄÄÄ¯ˇˇˇˇ *ORGANIZATIONöÄÄÄ¯ˇˇˇˇ	 	*ORGANIZATION»

InINO

theDTO

pastNNO
	
,,O

MedicaidNNPORGANIZATION

wasVBDO

80CDO

toTOO

90CDO

percentNNO

ofINO

theDTO

totalJJO

marketNNO

forINO

someDTO

high-endJJO

antipsychoticJJO

drugsNNSO
	
,,O

''''O

Mr.NNPPERSON

VerdierNNPPERSON

saidVBDO
	
..OõÄÄÄ¯ˇˇˇˇ *PERSONúÄÄÄ¯ˇˇˇˇ *ORGANIZATIONù

OverINO

allDTO
	
,,O

theDTO

MedicaidNNPO


best-priceJJO

rebatesNNSO

haveVBPO

averagedVBNO

aboutINO

15CDO

percentNNO

ofINO

theDTO

listNNO

pricesNNSO

ofINO

theDTO

manufacturersNNSO
	
,,O

butCCO

someDTO

statesNNSO
	
,,O

	includingVBGO


CaliforniaNNPLOCATION
	
,,O

NewNNPLOCATION

YorkNNPLOCATION

andCCO

MaineNNPLOCATION

haveVBPO

obtainedVBNO

evenRBO

largerJJRO

rebatesNNSO
	
,,O

	ProfessorNNPO

SchondelmeyerNNPPERSON

saidVBDO
	
..OùÄÄÄ¯ˇˇˇˇ& &*PERSONAûÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000028238 *LOCATIONAüÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000054dd5d *LOCATIONA†ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000000d0f6 *LOCATION“

NowRBO
	
,,O

underINO

PartNNORGANIZATION

DNNPORGANIZATION
	
,,O

allDTO

sortsNNSO

ofINO

priceNNO

dealsNNSO

willMDO

beVBO


negotiatedVBNO

byINO

dozensNNSO

ofINO

MedicareNNPORGANIZATION

drugNNO

plansNNSO
	
,,O

largeJJO

andCCO

smallJJO
	
..O°ÄÄÄ¯ˇˇˇˇ *ORGANIZATION¢ÄÄÄ¯ˇˇˇˇ *ORGANIZATIONÀ

TheDTO

pricesNNSO

willMDO

beVBO

reportedVBNO

toTOO

MedicareNNPORGANIZATION
	
,,O

butCCO

underINO


aDTO

	provisionNNO

ofINO

theDTO

lawNNO

pushedVBNO

byINO

industryNNO

	lobbyistsNNSO
	
,,O

theyPRPO

willMDO

	otherwiseRBO

beVBO

keptVBNO

secretJJO
	
..O£ÄÄÄ¯ˇˇˇˇ *ORGANIZATIONŸ

MarkNNPPERSON

B.NNPPERSON

	McClellanNNPPERSON
	
,,O

administratorNNO

ofINO

theDTO

federalJJO

agencyNNO

thatWDTO

overseesVBZO

MedicareNNPORGANIZATION

andCCO

MedicaidNNPO
	
,,O

saidVBDO

thatINO

theDTO

lowest-costJJO

plansNNSO

amongINO

theDTO

PartNNO

DNNPO

	offeringsNNSO

byINO


commercialJJO

insurersNNSO

wereVBDO

nowRBO

gettingVBGO

''''O

significantlyRBO

betterJJRO

pricesNNSO

thanINO

MedicaidNNPO
	
..O

''''O§ÄÄÄ¯ˇˇˇˇ *ORGANIZATION•ÄÄÄ¯ˇˇˇˇ  *PERSONk

ButCCO

hePRPO

didVBDO

notRBO

provideVBO

	specificsNNSO
	
..O·

Dr.NNPPERSON

	McClellanNNPPERSON

alsoRBO

notedVBDO

thatINO

hisPRP$O

agencyNNO

wasVBDO

	requiringVBGO

theDTO

statesNNSO

toTOO

returnVBO


aDTO

combinedVBNO

totalNNO

ofINO
	
$$O

5.8CDO

billionCDO

toTOO


WashingtonNNPLOCATION

fromINO

federalJJO

fundsNNSO

	dispensedVBNO

toTOO

theDTO

MedicaidNNPO

programNNO
	
..OA¶ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000000407bb *LOCATIONßÄÄÄ¯ˇˇˇˇ  *PERSONï

ThatDTO

moneyNNO

isVBZO

basedVBNO

onINO


aDTO

federalJJO

estimateNNO

ofINO

theDTO

amountNNO

statesNNSO

willMDO

beVBO

savingVBGO

byINO

noDTO

longerRBO

havingVBGO

toTOO

provideVBO

drugsNNSO

toTOO

theDTO

dual-eligiblesNNSO
	
..Oä

ButCCO

theDTO

statesNNSO
	
,,O

disparagingVBGO

thoseDTO

refundsNNSO

asINO

''JJO

	clawbacksNNSO
	
,,O

''''O

haveVBPO

disputedVBNO

theDTO

federalJJO

formulaNNO

thatWDTO

wasVBDO

theDTO

basisNNO

forINO

theDTO


repaymentsNNSO
	
..OÌ

LastJJO

monthNNO
	
,,O

theDTO

SupremeNNPORGANIZATION

CourtNNPORGANIZATION

declinedVBDO

toTOO

hearVBO


aDTO

caseNNO

filedVBNO

byINO

theDTO

	attorneysNNSO

generalJJO

ofINO

TexasNNPLOCATION

andCCO

fourCDO

otherJJO

statesNNSO

seekingVBGO

toTOO

quashVBO

theDTO

	repaymentNNO

formulaNNO

asINO

unconstitutionalJJO
	
..OA®ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000003abf2 *LOCATION©ÄÄÄ¯ˇˇˇˇ *ORGANIZATIONÀ

NowRBO

theDTO


plaintiffsNNSO
	
,,O

whichWDTO

alsoRBO

includeVBPO

KentuckyNNPLOCATION
	
,,O

MaineNNPLOCATION
	
,,O

MissouriNNPLOCATION
	
,,O

andCCO

NewNNPLOCATION

JerseyNNPLOCATION
	
,,O

areVBPO

expectedVBNO

toTOO

takeVBO

theDTO

fightNNO

toTOO

lowerJJRO

courtsNNSO
	
..OA™ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000002b60d *LOCATIONA´ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000002756f *LOCATIONA¨ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000028238	 	*LOCATIONA≠ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000002251d *LOCATIONÑ

TenCDO

otherJJO

statesNNSO

haveVBPO

	supportedVBNO

theDTO


plaintiffsNNSO
	
..O∏

TheDTO

statesNNSO

sayVBPO

theDTO

federalJJO

formulaNNO

assumesVBZO

higherJJRO

drugNNO

costsNNSO

thanINO

manyJJO

MedicaidNNPO

programsNNSO

haveVBPO

beenVBNO

spendingVBGO
	
..O

''''Oπ

WePRPO

getVBPO

32CDO

percentNNO

backRBO

inINO

drugNNO

rebatesNNSO
	
,,O

''''O

saidVBDO

JudeNNPPERSON

E.NNPPERSON

WalshNNPPERSON
	
,,O


aDTO

specialJJO

	assistantNNO

toTOO

GovernorNNPO

JohnNNPPERSON

BaldacciNNPPERSON

ofINO

MaineNNPLOCATION
	
..OAÆÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000028238 *LOCATION?ØÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000238810 *PERSON∞ÄÄÄ¯ˇˇˇˇ *PERSONö

ShePRPO

saidVBDO

MaineNNPLOCATION

'sPOSO

MedicaidNNPO

drugNNO

costsNNSO

wereVBDO

risingVBGO

onlyRBO


2CDO

percentNNO

toTOO


3CDO

percentNNO


aDTO

yearNNO
	
,,O

comparedVBNO

withINO

nationalJJO

trendsNNSO

thatWDTO

areVBPO

threeCDO

toTOO

fourCDO

timesNNSO

thatINO
	
..OA±ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000000028238 *LOCATIONÃ

TheDTO

drugNNO

	companiesNNSO
	
,,O

forINO

theirPRP$O

partNNO
	
,,O

haveVBPO

playedVBNO

downRPO

theDTO

sizeNNO

ofINO

theDTO

expectedVBNO

windfallNNO

fromINO

MedicaidNNPO

transfereesNNSO
	
..Oé

AndCCO

BushNNPPERSON

administrationNNO

	officialsNNSO

sayVBPO

theyPRPO

doVBPO

notRBO

knowVBO

howWRBO

muchJJO

theyPRPO

willMDO

endVBO

upRPO

spendingNNO

onINO

thoseDTO

peopleNNSO
	
..O

''''O?≤ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000000c41f3 *PERSON¡

NoDTO

oneNNO

isVBZO

willingJJO

toTOO


quantifyitVBO
	
,,O

''''O

saidVBDO

Dr.NNPPERSON

AndersonNNPPERSON
	
,,O

theDTO


PrudentialNNPORGANIZATION

analystNNO
	
..O≥ÄÄÄ¯ˇˇˇˇ *ORGANIZATION¥ÄÄÄ¯ˇˇˇˇ	 
*PERSON®

InINO

oneCDO

ofINO

theDTO

fewJJO

publicJJO

commentsNNSO

byINO


aDTO

drugNNO

companyNNO

officialNNO
	
,,O

DericaNNPPERSON

W.NNPPERSON

RiceNNPPERSON
	
,,O

chiefJJO

	financialJJO

officerNNO

ofINO

EliNNPORGANIZATION

LillyNNPORGANIZATION
	
,,O

toldVBDO

analystsNNSO

onINO


aDTO


conferenceNNO

callNNO

inINO

AprilNNPO

thatINO

LillyNNPLOCATION

expectedVBDO

''''O

modestJJO

priceNNO

benefitsNNSO

dueJJO

toTOO

lowerVBO

rebatesNNSO

asINO

patientsNNSO

moveVBPO

fromINO

MedicaidNNPO

toTOO

PlanNNPO

D.NNPO

''''O

ZyprexaNNPPERSON
	
,,O


aDTO

LillyNNPORGANIZATION

drugNNO

forINO

schizophreniaNNO
	
,,O

isVBZO

anotherDTO


medicationNNO

widelyRBO


prescribedVBNO

forINO

MedicaidNNPO

patientsNNSO
	
..OEµÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000000bec307 7*ORGANIZATION∂ÄÄÄ¯ˇˇˇˇ4 4*PERSONA∑ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000000bec30! !*LOCATIONE∏ÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f800000000071c2c0 *ORGANIZATION?πÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f8000000007bd59c0 *PERSONÔ

TheDTO

drugNNO

makersNNSO

doVBPO

haveVBO

reasonNNO

toTOO

worryVBO

aboutINO

long-runJJO

	prospectsNNSO

underINO

theDTO

vastJJO

newJJO

MedicareNNPORGANIZATION

PartNNORGANIZATION

DNNPO

programNNO
	
..O∫ÄÄÄ¯ˇˇˇˇ *ORGANIZATION∆

ThereEXO

areVBPO

	currentlyRBO

81CDO

PartNNO

DVBDO

drugNNO

planNNO

sponsorsVBZO
	
,,O

largeJJO

andCCO

smallJJO
	
,,O

withINO

varyingVBGO

degreesNNSO

ofINO

negotiatingVBGO

powerNNO
	
..O≤

ButCCO

theDTO

plansNNSO

areVBPO

expectedVBNO


eventuallyRBO

toTOO

mergeVBO

intoINO


aDTO

handfulNNO

ofINO

largeJJO

	survivorsNNSO
	
,,O

eachDTO

ofINO

themPRPO


presumablyRBO

havingVBGO

moreJJRO


bargainingNNO

powerNNO

withINO

drugNNO

	companiesNNSO
	
..O¨


ADTO

furtherJJO

concernNNO

isVBZO

thatINO

asINO

theDTO

trueJJO

costsNNSO

ofINO

PartNNO

DNNPO

becomeVBNO

knownVBNO
	
,,O

CongressNNPORGANIZATION

mayMDO


eventuallyRBO

imposeVBO

spendingVBGO

ceilingsNNSO
	
..OEªÄÄÄ¯ˇˇˇˇ&/guid/9202a8c04000641f80000000000f0ca5 *ORGANIZATION–

ForINO

nowRBO

thoughRBO
	
,,O

asINO

theDTO

drugNNO

industryNNO

beginsVBZO

toTOO

reportVBO

itsPRP$O

	quarterlyJJO

profitsNNSO
	
,,O

theDTO

marketNNO

forINO

thoseDTO

6.5CDO

millionCDO

poorJJO

peopleNNSO

isVBZO

likelyJJO

toTOO

lookVBO

ratherRBO

	lucrativeJJO
	
..O!

MARKETNNO

PLACENNO